Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

732
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
732
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

685
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
685
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

820
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
820
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1000
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1000
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

2
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
2
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Behavioral and Molecular Effects of Kamikihito and Mesenchymal Stem Cells in a Two-hit Model of Treatment-resistant Depression.

Current neuropharmacology·2026
Same author

Regional mechanical differences in hamstring muscles after removal of surrounding connective tissue.

Journal of biomechanics·2026
Same author

Velocity-Dependent Stress Changes in the Hamstring Muscle-Tendon Complex: A Study Using Human Cadavers.

Translational sports medicine·2026
Same author

Loss of Nonhematopoietic Osteopontin Weakens the Intestinal Barrier and Alters the Microbiome and Metabolome in Mice.

Gastro hep advances·2026
Same author

Regional changes in shear modulus of the biceps femoris long head following load application to the biceps femoris short head.

Journal of biomechanics·2025
Same author

Breaking points of human hamstring muscle-tendon complex: A cadaveric study.

Journal of the mechanical behavior of biomedical materials·2025

Related Experiment Video

Updated: Apr 18, 2026

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.9K

Stem cell therapy for inflammatory bowel disease.

Kanna Nagaishi1, Yoshiaki Arimura, Mineko Fujimiya

  • 1Second Department of Anatomy, Sapporo Medical University, S-1, W-17, Chuo-ku, Sapporo, 060-8556, Japan, kanna@sapmed.ac.jp.

Journal of Gastroenterology
|January 26, 2015
PubMed
Summary

Mesenchymal stem cells (MSCs) offer a promising new avenue for treating inflammatory bowel disease (IBD) by modulating immune responses and promoting tissue repair. Optimizing MSC therapy requires understanding their mechanisms to advance regenerative medicine for IBD.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

619
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Related Experiment Videos

Last Updated: Apr 18, 2026

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.9K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

619
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Area of Science:

  • Regenerative Medicine
  • Gastroenterology
  • Immunology

Background:

  • Inflammatory bowel disease (IBD) presents significant challenges, with current treatments like allogeneic hematopoietic stem cell transplantation having risks.
  • Mesenchymal stem cells (MSCs) are emerging as a potential alternative therapy for intractable diseases, including IBD.
  • The therapeutic potential of MSCs lies in their multifaceted roles as cell providers, immune modulators, and trophic factor producers.

Purpose of the Study:

  • To explore the potential of mesenchymal stem cells (MSCs) as a novel therapeutic strategy for inflammatory bowel disease (IBD).
  • To highlight the importance of optimizing MSC therapy by understanding their underlying mechanisms of action.
  • To bridge the gap between basic stem cell research and clinical application in regenerative medicine for IBD.

Main Methods:

  • Review of current research on MSCs and their application in IBD.
  • Analysis of the proposed mechanisms of MSC therapeutic action, including immune modulation and tissue repair.
  • Discussion of challenges and future directions for MSC-based regenerative medicine.

Main Results:

  • MSC therapy offers a potential alternative to existing IBD treatments, with therapeutic effects not solely dependent on engraftment.
  • Optimization of MSC-derived trophic factors can enhance immune regulation and tissue repair, crucial for IBD treatment.
  • Understanding the mechanisms of MSC action is critical for overcoming current limitations in clinical translation.

Conclusions:

  • Mesenchymal stem cells (MSCs) hold significant promise for the future treatment of inflammatory bowel disease (IBD).
  • Further research into the mechanisms of MSCs is essential for optimizing their therapeutic efficacy and advancing regenerative medicine.
  • A paradigm shift towards evidence-based optimization of MSC therapy is needed to conquer IBD.